GE
PTCT icon

General Electric’s PTC Therapeutics PTCT Stock Holding History

General Electric’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-63,740
Closed -$1.08M – 218
2013
Q4 		$1.08M Hold
63,740
– – 0.01% 194
2013
Q3 		$1.37M Buy
+63,740
New +$1.11M 0.01% 191

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

General Electric's PTCT Position: Q1 2014 in Review

General Electric sold out of PTC Therapeutics (PTCT) in Q1 2014, closing a stake of 63,740 shares — an estimated $1.08M sold.

General Electric first reported a position in PTCT in Q3 2013 and held it in 2 quarters. The position peaked at $1.37M in Q3 2013. 65 funds tracked by Wall St. Rank hold PTCT as of Q1 2014.

  • General Electric reported no remaining PTC Therapeutics position as of Q1 2014 after selling out during the quarter.
  • General Electric sold 63,740 PTC Therapeutics shares in Q1 2014, an estimated $1.08M.
  • General Electric first reported a position in PTC Therapeutics in Q3 2013 and held it in 2 quarters.
  • General Electric's PTC Therapeutics position peaked at $1.37M in Q3 2013.
  • 65 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2014.

Based on General Electric's 13F filing for Q1 2014, filed 13 May 2014.